ERBB2 and breast cancer: Among all subtypes of breast cancer, triple-negative breast cancer is responsible for 15 to 20% of breast cancer, and is the most aggressive for poor therapeutic prognosis due to its major characteristic of the lack of expression of human epidermal growth factor receptor 2 (HER2/neu), oestrogen receptor and progesterone receptor (Smolarz et al. 2022).